Protein kinase inhibitors are an experimental new class of drugs which are highly focused, targeting the enzymes which modify certain proteins, which in turn affect cancer growth. One such drug is Eli Lilly's enzastaurin, currently in clinical trials.
In a Phase II trial reported in 2010, 25% of 66 patients responded to the drug and another 40% had stable disease. Only 1 patient achieved complete remission. The duration of response was not reached when the study was published, with responses ranging (at that time) from about two months to almost two years.
Published Trial Results
L. Schwartzberg et al. "Enzastaurin in Patients with Follicular Lymphoma." Journal of Clinical Oncology (2010).
No comments:
Post a Comment